A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus
Status:
Withdrawn
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
Discoid lupus erythematosus is a chronic inflammatory skin condition and may lead to itch,
skin pain, open sores, scarring, disfigurement and hair loss. Studies have shown that IL-17A
may play a major role in inflammation and in the pathogenesis of discoid lupus. Treatment of
discoid lupus sometimes is a challenge and unresponsive to current therapies. Secukinumab, an
anti-IL-17A monoclonal antibody has been safe and effective in the treatment of psoriasis.
The investigators propose to study the efficacy and safety of secukinumab in discoid lupus.